NEJ002

一行要約

EGFR 変異陽性の未治療 NSCLC における Gefitinib vs Carboplatin/Paclitaxel の日本 phase III。PFS HR 0.30 (10.8 vs 5.4 mo) という圧倒的な efficacy を示し、EGFR 変異を biomarker とした 1L TKI 治療の有効性を世界に先駆けて前向きに確認した foundational trial。WJTOG3405 と並び、日本から発信された precision medicine の milestone。

試験デザイン

• 対象: EGFR 変異陽性 (ex19del or L858R) の未治療進行 NSCLC、PS 0-2、N=230 (1:1)、日本国内 43 施設
• 介入群 (n=114) : Gefitinib 250 mg/day
• 対照群 (n=116) : Carboplatin AUC6 + Paclitaxel 200 mg/m2 Q3W、最大 3 cycles (その後は treatment-free observation)
• 層別化: 性別、PS (0-1 vs 2)、施設
• 主要評価項目: PFS
• 登録 ID: UMIN000000539
• Cross-over: 化療群は PD 後に Gefitinib への cross-over が許容され、大多数が後治療で Gefitinib を受けた

主要結果

• PFS (primary) : HR 0.30 (95% CI 0.22–0.41, p<0.001)、median 10.8 vs 5.4 mo
• ORR: 73.7% vs 30.7%
• OS: Median 27.7 vs 26.6 mo (HR 0.887, p=0.483) — crossover の影響で有意差なし
• Mutation 別: ex19del PFS HR 0.19、L858R PFS HR 0.47 — ex19del でより大きな benefit (この傾向は後続試験でも一貫)
• Grade ≥3 AE: Gefitinib で肝機能障害 26.3%、皮疹 5.3%。化療群では骨髄抑制 (好中球減少 Grade ≥3: 65.5%) が主
• ILD (間質性肺疾患) : Gefitinib 群で 5.3% (日本人特有の高頻度)、致死的 ILD 1 例

臨床的意義

• Biomarker-driven precision medicine の confirmation: IPASS (2009、EGFR 選択なし → post-hoc EGFR+ 解析) が示唆した EGFR 変異選択 TKI 戦略を、前向き EGFR 変異陽性選択で世界初確認
• 日本発 evidence の global impact: WJTOG3405 と同時期に発表され、EGFR+ NSCLC 1L の global standard を化学療法から EGFR-TKI に転換。全世界のガイドライン改訂を主導
• ex19del / L858R differential: ex19del での PFS HR 0.19 は突出しており、EGFR 変異サブタイプ間の heterogeneity を初めて前向きに可視化
• 日本人 ILD リスク: Gefitinib の ILD 発生率が 5.3% と高く、日本人における EGFR-TKI 治療の安全管理の重要性を強調。その後の安全性基準策定に影響
• 後続試験への基盤: NEJ009 (Gefitinib + chemo)、NEJ026 (Gefitinib + bevacizumab) 等の日本主導試験への発展

Open Questions

• NEJ002 cohort の real-world long-term OS: 10 年以上の follow-up による ultra-long survivor の特徴
• Ex19del / L858R differential のメカニズム: 構造的差異 (α-C helix displacement) と下流 signaling の違い
• ILD 予測バイオマーカー: KL-6 / SP-D 等の既存マーカーに加え、遺伝的素因の解明

重要論文 Top 10

1. ★★★★★ Maemondo et al. NEnglJMed 2010 — Primary publication — PFS HR 0.30、EGFR+ 1L TKI の foundational evidence
2. ★★★★ Inoue et al. JClinOncol 2008 (NEJ001) — Phase II — PS 不良 EGFR+ への Gefitinib で ORR 66%
3. Mitsudomi et al. LancetOncol 2010 (WJTOG3405) — Companion trial — 同時期発表で evidence を相互補強
4. Mok et al. (IPASS) — IPASS — EGFR selection の概念を初めて示唆
5. Soria et al. (FLAURA) — 3rd-gen Osimertinib — NEJ002 以降の世代進化

関連エンティティ・概念

• 薬剤: Gefitinib / Carboplatin / Paclitaxel
• 関連試験: WJTOG3405 (companion trial) / IPASS (selection 概念の先駆) / FLAURA (3rd-gen 1L) / EURTAC (Western EGFR+ 1L)
• 関連遺伝子: EGFR (ex19del, L858R)
• ドメイン: lung-cancer-treatment

関連論文

直近 30 件のみ表示中 (関連 37 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Oncogene and genetics

• Du et al. MolCancer 2018 — Mechanisms of receptor tyrosine kinase activation in cancer

Clinical-NSCLC-Driver-Other

• Johnson et al. JClinOncol 2014 — Recent clinical advances in lung cancer management

Clinical-NSCLC-EGFR

• Inoue et al. AnnOncol 2013 — Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for
• Lee et al. AnnOncol 2013 — Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with
• Sugawara et al. AnnOncol 2015 — Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously
• Paz-Ares et al. AnnOncol 2017 — Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer overall survival
• Rolfo et al. CancerTreatRev 2014 — Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
• Bronte et al. CritRevOncolHematol 2014 — Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment
• Oizumi et al. ESMOOpen 2018 — Updated survival outcomes of NEJ005TCOG0902 a randomised phase II study of concurrent versus sequential alternating
• Han et al. JClinOncol 2012 — First-SIGNAL first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma
• Lee et al. JClinOncol 2015 — Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after
• Cho et al. JClinOncol 2020 — Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations A multicenter, open-label,
• Hosomi et al. JClinOncol 2020 — Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor
• Haratake et al. JTOClinResRep 2020 — Optimizing sequential treatment with EGFR tyrosine kinase inhibitor with a simulation of the T790M mutation rate in
• Watanabe et al. JThoracOncol 2014 — Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q
• Zhou et al. LancetOncol 2011 — Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell
• Rosell et al. LancetOncol 2012 — Erlotinib versus standard chemotherapy as first-line treatment for european patients with advanced EGFR
• Wu et al. LancetOncol 2014 — Afatinib versus cisplatin plus gemcitabine for first-line treatment of asian patients with advanced non-small-cell lung
• Yang et al. LancetOncol 2015 — Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations a
• Fukuhara et al. LungCancer 2015 — Factors associated with a poor response to gefitinib in the NEJ002 study smoking and the L858R mutation
• OKane et al. LungCancer 2017 — Uncommon EGFR mutations in advanced non-small cell lung cancer
• Maemondo et al. NEnglJMed 2010 — Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
• Sequist et al. NEnglJMed 2015 — Rociletinib in EGFR-mutated non-small-cell lung cancer
• Mok et al. NEnglJMed 2017 — Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer
• Soria et al. NEnglJMed 2018 — Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer
• Ramalingam et al. NEnglJMed 2020 — Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC
• Asao et al. RespirInvestig 2019 — Resistance to molecularly targeted therapy in non-small-cell lung cancer
• Carnio et al. SeminOncol 2014 — Extending survival of stage IV non-small cell lung cancer

Clinical-NSCLC-HER2

• Friedlaender et al. NatRevClinOncol 2022 — EGFR and HER2 exon 20 insertions in solid tumours from biology to treatment

Clinical-NSCLC-ROS1

• Janne et al. JClinOncol 2012 — ROS1 rearrangements in lung cancer a new genomic subset of lung adenocarcinoma